Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach
American Society of Clinical Oncology Educational Book · 2026
DOI: 10.1200/edbk-26-520666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026. Verfasst von Dame Idossa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Precision Medicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by lack of estrogen receptor expression, progesterone receptor expression, and human epidermal growth factor 2 overexpression/amplification. Given its generally aggressive biology, current guidelines recommend systemic therapy for most patients, with anthracycline- and taxane-based regimens being historically preferred. However, the clinical outcomes of patients with stage I TNBC and the benefit (or lack thereof) of (neo)adjuvant chemotherapy have not been prospectively evaluated as this population has largely been excluded from prospective randomized clinical trials. As such, management decisions for stage I TNBC are typically extrapolated from trials enrolling patients with stage II or III TNBC or based on retrospective analyses. Currently, the primary factor influencing systemic therapy decisions is the anatomic stage, without other biomarkers clinically used to guide systemic therapy. This review summarizes the existing evidence supporting current and emerging systemic therapy strategies for stage I TNBC, with a special focus on treatment de-escalation and promising biomarkers that can advance personalized treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
- University of California, Los Angeles, Los Angeles, CA.
- Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
ORCID-Profile: Roberto A Leon-Ferre
Zitieren
APA
Idossa, D., Hennessy, M. A., LeVee, A., Nanda, R., McArthur, H., & Leon-Ferre, R. A. (2026). Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-26-520666
Vancouver
Idossa D, Hennessy MA, LeVee A, Nanda R, McArthur H, Leon-Ferre RA. Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. American Society of Clinical Oncology Educational Book. 2026. doi:10.1200/edbk-26-520666
BibTeX
@article{Idossa2026,
author = {Idossa, Dame and Hennessy, Maeve A and LeVee, Alexis and Nanda, Rita and McArthur, Heather and Leon-Ferre, Roberto A},
title = {Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
doi = {10.1200/edbk-26-520666}
}
EUVIMED